Macsita-M 50/500 Tablet is a combination oral antidiabetic medication containing Sitagliptin 50 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the incretin system by preventing the degradation of incretin hormones, thereby increasing insulin release and decreasing glucagon levels in a glucose-dependent manner. Metformin, a biguanide, primarily acts by reducing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake and utilization. The synergistic action of these two agents helps in achieving better glycemic control by targeting multiple pathophysiological defects associated with type 2 diabetes. Macsita-M 50/500 is typically prescribed as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled on either agent alone or when combination therapy is appropriate. It is important to monitor renal function prior to and during treatment due to the risk of metformin-associated lactic acidosis, especially in patients with renal impairment. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea. This medication should be used under medical supervision with regular monitoring of blood glucose levels and renal function.